True

The NIPT Technology


In 1997, the presence of fetal DNA in maternal plasma and serum was reported by a group of professors from CUHK. It is now known that those cell-free DNA in the maternal circulation during pregnancy comes from the fetoplacental unit, most of which is shed from the placenta. By a single blood draw, is able to screen for fetal chromosomal aneuploidies such as Down Syndrome (T21), Edwards Syndrome (T18) and Patau Syndrome (T13) etc.


 
 



How the test is done?

  utilizes Next Generation Sequencing technique and bioinformatics analysis on both maternal DNA and cell free placental DNA found in maternal blood. Compared to traditional screening methods based on nuchal translucency or maternal age,    is more sensitive,reliable, accurate and informative.

 

  • During pregnancy, the fetus releases some of the cell-free DNA into the blood circulation of its mother.
  • DNA from the fetus is obtained by drawing 10mL of maternal blood.
  • Safe T21 express analyses the circulating cell-free DNA molecules by NGS technology followed by bioinformatics analysis.
  • The report containing the genetic information of the fetus will be available in 5 working days.

Why choose 

offers screening for twins, triplets, and in vitro fertilization (IVF) cases

 

 
Accurate result and fast turnaround time
- Report is available in around 5 working days- Positive / Negative results- Endorsed by CUHK Obstetrics and Gynaecology medical professionals
 
Early detection that is safe and comprehensive
- ONLY 10mL of maternal blood is required- No fasting is needed- No miscarriage risks
 
All rounded care
- Support from CUHK professors for positive or special cases- Sponsorship for positive cases invasive diagnostic test laboratory test fee (valued at HKD$4000)
 
Exclusive licensee in Hong Kong
- Exclusive patent from the Chinese University of Hong Kong for the provision of NIPT services in HK

Reference

  • YM Lo et al. 1997, ‘Presence of fetal DNA in maternal plasma and serum’, The lancet, vol. 350, pp.485-487